Furthermore, decreasing NFAT activity through administration of an inhibitory peptide (VIVIT) was shown to be an effective treatment for pressure overload-induced cardiac hypertrophy in a rat animal model preventing increased heart weight and serum concentrations of brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) [24]. Here, NPPA is linked to cardiac hypertrophy.